The 2021 American Heart Association Scientific Sessions featured several important clinical studies. The AVATAR study investigated whether early surgical aortic valve replacement (SAVR) is beneficial in asymptomatic patients with severe aortic stenosis. The study found that early SAVR significantly reduced the risk of major adverse cardiovascular events compared to conservative treatment. The study included 157 patients with asymptomatic severe aortic stenosis, and the primary endpoint was a lower rate of death, myocardial infarction, stroke, or unplanned hospitalization for heart failure in the early surgery group compared to the conservative treatment group. Another study examined whether tricuspid valve repair should be performed during mitral valve surgery in patients with concomitant severe tricuspid regurgitation. The study found that concomitant tricuspid valve repair reduced the risk of tricuspid regurgitation progression and improved outcomes compared to isolated mitral valve surgery. The CRAVE study explored whether coffee consumption increases the risk of arrhythmias. The study found that coffee consumption increased ventricular premature beats in rapid caffeine metabolizers but had no significant effect on supraventricular arrhythmias. Coffee also increased physical activity but reduced sleep duration. The EMPEROR-Preserved trial evaluated the effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). The study found that empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients with HFpEF. The trial also showed that empagliflozin improved quality of life in these patients. The EMPULSE trial examined whether empagliflozin is effective in treating acute decompensated heart failure. The study found that empagliflozin significantly reduced the risk of hospitalization and improved quality of life in patients with acute decompensated heart failure. The study on PCSK9 inhibitors evaluated the effectiveness of an oral PCSK9 inhibitor, MK-0616, in lowering LDL cholesterol. The study found that MK-0616 was well tolerated and significantly reduced plasma PCSK9 levels, leading to a significant reduction in LDL cholesterol levels. The REVERSE-IT trial evaluated the effectiveness of PB2452 in reversing the antiplatelet effect of ticagrelor. The study found that PB2452 significantly reversed the antiplatelet effect of ticagrelor and improved haemostasis in patients requiring reversal of ticagrelor action. The study also found that PB2452 was safe and effective in patients requiring urgent surgical procedures or invasive procedures associated with major bleeding risk.The 2021 American Heart Association Scientific Sessions featured several important clinical studies. The AVATAR study investigated whether early surgical aortic valve replacement (SAVR) is beneficial in asymptomatic patients with severe aortic stenosis. The study found that early SAVR significantly reduced the risk of major adverse cardiovascular events compared to conservative treatment. The study included 157 patients with asymptomatic severe aortic stenosis, and the primary endpoint was a lower rate of death, myocardial infarction, stroke, or unplanned hospitalization for heart failure in the early surgery group compared to the conservative treatment group. Another study examined whether tricuspid valve repair should be performed during mitral valve surgery in patients with concomitant severe tricuspid regurgitation. The study found that concomitant tricuspid valve repair reduced the risk of tricuspid regurgitation progression and improved outcomes compared to isolated mitral valve surgery. The CRAVE study explored whether coffee consumption increases the risk of arrhythmias. The study found that coffee consumption increased ventricular premature beats in rapid caffeine metabolizers but had no significant effect on supraventricular arrhythmias. Coffee also increased physical activity but reduced sleep duration. The EMPEROR-Preserved trial evaluated the effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). The study found that empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients with HFpEF. The trial also showed that empagliflozin improved quality of life in these patients. The EMPULSE trial examined whether empagliflozin is effective in treating acute decompensated heart failure. The study found that empagliflozin significantly reduced the risk of hospitalization and improved quality of life in patients with acute decompensated heart failure. The study on PCSK9 inhibitors evaluated the effectiveness of an oral PCSK9 inhibitor, MK-0616, in lowering LDL cholesterol. The study found that MK-0616 was well tolerated and significantly reduced plasma PCSK9 levels, leading to a significant reduction in LDL cholesterol levels. The REVERSE-IT trial evaluated the effectiveness of PB2452 in reversing the antiplatelet effect of ticagrelor. The study found that PB2452 significantly reversed the antiplatelet effect of ticagrelor and improved haemostasis in patients requiring reversal of ticagrelor action. The study also found that PB2452 was safe and effective in patients requiring urgent surgical procedures or invasive procedures associated with major bleeding risk.